The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...

CKD and ESRD can have unpleasant cutaneous manifestations, including alopecia, but there are several helpful approaches to mitigating hair loss.

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable.

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

It’s time that insurance recognizes wigs as necessary medical expenses for those suffering from conditions like alopecia, ...

Wearing a hat won't make you bald in and of itself, Thacker says.

By understanding the essential role vitamins play in hair growth and scalp health, one can take proactive steps to prevent ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has announced the results of a groundbreaking study conducted in Japan, which underscores the technological advantages of its XTRAC® Excimer Laser over ...

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...